SCHEMBL3306841

SCHEMBL3306841

CC(C)C(=O)NC1CCN(Cc2ccccc2)CC1

nearest known ligand 0.73

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 8/20 0.68
ALDH1A1 P00352 1/20 0.67
CYP2C19 P33261 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
DRD4 P21917 2/20 0.64
DRD2 P14416 1/20 0.64
DRD3 P35462 1/20 0.64
KMT2A Q03164 1/20 0.64
POLB P06746 1/20 0.63
DPP7 Q9UHL4 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13396905 0.92 BACE1 (0.63) SIGMAR1ALDH1A1CYP2C19SMN1; SMN2DRD4
SCHEMBL4848461 0.89 SIGMAR1 (0.65) SIGMAR1ALDH1A1CYP2C19SMN1; SMN2DRD4
SCHEMBL29712058 0.89 SIGMAR1 (0.65) SIGMAR1ALDH1A1CYP2C19SMN1; SMN2DRD4
SCHEMBL14116101 0.88 SIGMAR1 (0.63) SIGMAR1ALDH1A1CYP2C19SMN1; SMN2
Benzene SCHEMBL10799860 0.87 SIGMAR1 (0.62) SIGMAR1ALDH1A1CYP2C19SMN1; SMN2DRD4
SCHEMBL6207514 0.85 SIGMAR1 (0.60) SIGMAR1ALDH1A1CYP2C19SMN1; SMN2DRD4
SCHEMBL4846139 0.85 SIGMAR1 (0.60) SIGMAR1ALDH1A1CYP2C19SMN1; SMN2DRD4
SCHEMBL4846164 0.85 SIGMAR1 (0.60) SIGMAR1ALDH1A1CYP2C19SMN1; SMN2DRD4
SCHEMBL25139432 0.84 ALDH1A1 (0.62) ALDH1A1CYP2C19DRD4DRD2DRD3
SCHEMBL3164487 0.84 SIGMAR1 (0.74) SIGMAR1CYP2C19DRD4DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101796027-A N-piperidin-4-ylmethyl-amide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH AS 2010-08-04 CN claimed
US-10167299-B2 1-(3-aminopropyl) substituted cyclic amine compounds, preparation method therefor, and pharmaceutical compositions and uses thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2019-01-01 US disclosed
US-20170129916-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS HETERO RESEARCH FOUNDATION (IN) 2017-05-11 US disclosed
US-20170129916-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS HETERO RESEARCH FOUNDATION (IN) 2017-05-11 US disclosed
US-20170044187-A1 1-(3-AMINOPROPYL) SUBSTITUTED CYCLIC AMINE COMPOUNDS, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2017-02-16 US disclosed
US-20170044187-A1 1-(3-AMINOPROPYL) SUBSTITUTED CYCLIC AMINE COMPOUNDS, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2017-02-16 US disclosed
US-20140065070-A1 METHODS OF PREPARING TRIAZOLE-CONTAINING RADIOIODINATED COMPOUNDS MCMASTER UNIVERSITY (CA) 2014-03-06 US disclosed
CN-101796027-A N-piperidin-4-ylmethyl-amide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH AS 2010-08-04 CN disclosed
US-20100093795-A1 Piperidine Derivative Used for Treating Chemokine Receptor 5 Mediated Diseases ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093795-A1 Piperidine Derivative Used for Treating Chemokine Receptor 5 Mediated Diseases ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-7294636-B2 Chemical compounds ASTRAZENECA AB (SE) 2007-11-13 US disclosed
US-20070167442-A1 Chemical compounds ASTRAZENECA AB (SE) 2007-07-19 US disclosed
WO-2007066201-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2007-06-14 WO disclosed
WO-2007066201-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2007-06-14 WO disclosed
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma PHARMACIA CORPORATION 2007-04-05 US disclosed
US-20070015788-A1 N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis ASTRAZENECA AB (SE) 2007-01-18 US disclosed
EP-1742934-A2 PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 AstraZeneca AB (SE) 2007-01-17 EP disclosed
EP-1625120-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2006-02-15 EP disclosed
WO-2005101989-A2 PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 ASTRAZENECA AB (SE) 2005-11-03 WO disclosed
WO-2004099178-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015788-A1 N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis CCR5, CCR2, CX3CR1 SIGMAR1 670/4885ALDH1A1 531/4885CYP2C19 619/4885
US-20100093795-A1 Piperidine Derivative Used for Treating Chemokine Receptor 5 Mediated Diseases CCR5, CCL5, CXCR5 SIGMAR1 625/4885ALDH1A1 889/4885CYP2C19 3348/4885
US-20170129916-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS BET1, PRR12, PREP SIGMAR1 4650/4885ALDH1A1 4180/4885CYP2C19 2969/4885
US-20140065070-A1 METHODS OF PREPARING TRIAZOLE-CONTAINING RADIOIODINATED COMPOUNDS CYP11B1, CYP11B2, PAICS SIGMAR1 1461/4885ALDH1A1 645/4885CYP2C19 178/4885
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma MAPK1, MAPK3, MAPK4 SIGMAR1 2342/4885ALDH1A1 1079/4885CYP2C19 3141/4885
US-20070167442-A1 Chemical compounds CCR5, CXCR3, CX3CR1 SIGMAR1 442/4885ALDH1A1 586/4885CYP2C19 337/4885
US-20170044187-A1 1-(3-AMINOPROPYL) SUBSTITUTED CYCLIC AMINE COMPOUNDS, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF CCR5, CCR1, CCRL2 SIGMAR1 928/4885ALDH1A1 297/4885CYP2C19 807/4885
US-10167299-B2 1-(3-aminopropyl) substituted cyclic amine compounds, preparation method therefor, and pharmaceutical compositions and uses thereof CCR5, CCRL2, CCR1 SIGMAR1 1086/4885ALDH1A1 823/4885CYP2C19 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.